Clinical Trials Details

NRG-GY018 (Endometrial)

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Objective

The clinical trial was temporarily closed to accrual on April 6, 2020.

Clinical Trial Categories

  • Cancers and Other Neoplasms